A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was incorporated in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.
Financial Summary
| Share Statistics | BCHMY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6,933.9 | $1,790.4 | 72% |
|
| Shares Out (Mil) | 92.9 | 94.8 | 61% |
|
| Institutional Ownership | 49.2% | 90.0% | 23% |
|
| Float (Mil) | 74.7 | 69.9 | 56% |
|
| Beta | 0.81 | 1.20 | 48% |
|
| Avg Daily Volume (000s) | 6 | 814 | 14% |
|
| Price Change (52-week) |
(0.8%) | 80.2% | 45% |
|
| Growth | BCHMY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 14.0% | 7.8% | 70% |
|
| Net Income (5yr) | 16.3% | (13.7%) | 66% |
|
| EPS (5yr) | 14.7% | 0.7% | 55 |
|
| Dividends (5yr) | 9.1% | 0.0% | 81% |
|
| Cash Flow (5yr) | (98.3%) | (15.0%) | 1% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | BCHMY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $877 | $785 | 49% |
|
| Net Income (TTM) (Mil) | $184 | ($14) | 67% |
|
| EPS (TTM) | $2.455 | ($0.200) | 75% |
|
| Operating Cash Flow (TTM) (Mil) | $359 | $53 | 67% |
|
| Net Cash Flow (TTM) (Mil) | $28 | ($4) | 66% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $270 | 0% |
|
| Enterprise Value (Q1) (Mil) | $7,335 | $2,444 | 69% |
|
| Valuation | BCHMY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.92 | na |
|
| P/E | na | 43.7 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 5.3 | na |
|
| Ratios | BCHMY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 27.0% | 47.6% | 31% |
|
| Net Margin | 21.0% | (2.9%) | 80% |
|
| ROA | 7.0% | (2.8%) | 80% |
|
| ROE | 10.5% | (4.5%) | 59% |
|
| Liabilities to Assets | 38.3% | 43.0% | 29% |
|
| F-Score | na | 5 | na |
|
Bachem Holding AG did not pass any screens on 7/31/2026.
